Dean A S, Zignol M, Lumb R, Lalor M, Skrahina A, Floyd K
Global TB Programme, World Health Organization, Geneva, Switzerland.
Mycobacterium Reference Laboratory, Microbiology and Infectious Diseases Directorate, South Australia Pathology, Adelaide, South Australia, Australia.
Int J Tuberc Lung Dis. 2016 Jul;20(7):864-5. doi: 10.5588/ijtld.15.0977.
Until countries establish capacity for continuous surveillance systems, representative surveys of tuberculosis (TB) patients continue to improve our understanding of the burden of drug-resistant TB and help ensure appropriate allocation of resources. Although the available data are limited, the current recommendation of restricting surveys to sputum smear-positive patients is justified, given the greatly simplified logistics and only limited evidence in specific settings of an association between drug resistance and sputum smear status. Nonetheless, the relationship between drug resistance and sputum smear microscopy results may vary according to the setting and population under study. With the increasing availability and use of molecular diagnostics and the drive for universal drug susceptibility testing under the World Health Organization's End TB Strategy, substantially more data on drug resistance in the whole TB patient population should become available in the near future.
在各国建立持续监测系统的能力之前,对结核病(TB)患者进行代表性调查,仍有助于我们更好地了解耐多药结核病的负担,并有助于确保资源的合理分配。尽管现有数据有限,但鉴于后勤工作大大简化,且在特定环境中耐药性与痰涂片状态之间的关联证据有限,目前将调查限于痰涂片阳性患者的建议是合理的。尽管如此,耐药性与痰涂片显微镜检查结果之间的关系可能因所研究的环境和人群而异。随着分子诊断技术的日益普及和应用,以及在世界卫生组织《终止结核病战略》推动下进行普遍药敏试验,在不久的将来,关于全体结核病患者耐药性的更多数据应会可得。